NCT06827860View on ClinicalTrials.gov

Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

PHASE2RecruitingINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2028

Conditions
Multiple Myeloma in Relapse
Interventions
DRUG

Talquetamab

SC monotherapy starting with three step-up doses followed by the standard 800 μg/kg dose every other week. Cycles will be 28 days long.

DRUG

Daratumumab

SC at the standard dose (weekly for 2 cycles, every other week for 4 cycles, monthly thereafter)

Trial Locations (1)

10029

RECRUITING

Icahn School of Medicine at Mount Sinai, New York

All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Larysa Sanchez

OTHER

NCT06827860 - Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse | Biotech Hunter | Biotech Hunter